

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Shiro Fukuyama

Confirmation No: To be assigned

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: July 14, 2003

Examiner: To be assigned

For: Polypeptides Having Glucanotransferase Activity And Nucleic Acids Encoding Same

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references was filed in US application no. 09/687,360 filed October 13, 2000, the benefit of which is claimed under 35 USC 120. It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: July 14, 2003



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)</p>				Complete if Known												
<p>Substitute for form 1449A/PTO</p>				<table border="1"> <tr> <td>Application Number</td> <td>To be assigned</td> </tr> <tr> <td>Filing Date</td> <td>July 14, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Shiro Fukuyama</td> </tr> <tr> <td>Art Unit</td> <td>To be assigned</td> </tr> <tr> <td>Examiner Name</td> <td>To be assigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>6012.210-US</td> </tr> </table>	Application Number	To be assigned	Filing Date	July 14, 2003	First Named Inventor	Shiro Fukuyama	Art Unit	To be assigned	Examiner Name	To be assigned	Attorney Docket Number	6012.210-US
Application Number	To be assigned															
Filing Date	July 14, 2003															
First Named Inventor	Shiro Fukuyama															
Art Unit	To be assigned															
Examiner Name	To be assigned															
Attorney Docket Number	6012.210-US															
Sheet	1	of	3													

U.S PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	To be assigned
Sheet	2	of	3	Filing Date	July 14, 2003
				First Named Inventor	Shiro Fukuyama
				Art Unit	To be assigned
				Examiner Name	To be assigned
				Attorney Docket Number	6012.210-US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Terada et al., Applied and Environmental Microbiology, Vol. 65, No. 3, pp 910-915 (1999)	
		Takaha et al., The Journal of Biological Chemistry, Vol. 208, No. 2, pp. 1881-1895 (1998)	
		Kitahata et al., Agric. Biol. Chem., 53 (10), 2653-2659, 1989	
		Peat et al., J. Chem. Soc. 1956, 44-53	
		Kaneko et al., PIR Database Accession No. S74648, 25 Apr. 1997	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.